- Home
- TSHA vs WLKP Comparison
TSHA vs WLKP Comparison
Compare TSHA & WLKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- WLKP
- Stock Information
- Founded
- TSHA 2019
- WLKP 2014
- Country
- TSHA United States
- WLKP United States
- Employees
- TSHA N/A
- WLKP N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- WLKP Major Chemicals
- Sector
- TSHA Health Care
- WLKP Industrials
- Exchange
- TSHA Nasdaq
- WLKP Nasdaq
- Market Cap
- TSHA 728.4M
- WLKP 778.4M
- IPO Year
- TSHA 2020
- WLKP 2014
- Fundamental
- Price
- TSHA $3.36
- WLKP $21.87
- Analyst Decision
- TSHA Strong Buy
- WLKP
- Analyst Count
- TSHA 7
- WLKP 0
- Target Price
- TSHA $8.71
- WLKP N/A
- AVG Volume (30 Days)
- TSHA 3.5M
- WLKP 34.5K
- Earning Date
- TSHA 08-12-2025
- WLKP 11-04-2025
- Dividend Yield
- TSHA N/A
- WLKP 8.61%
- EPS Growth
- TSHA N/A
- WLKP N/A
- EPS
- TSHA N/A
- WLKP 1.49
- Revenue
- TSHA $8,098,000.00
- WLKP $1,101,803,000.00
- Revenue This Year
- TSHA N/A
- WLKP $8.90
- Revenue Next Year
- TSHA N/A
- WLKP $6.87
- P/E Ratio
- TSHA N/A
- WLKP $14.65
- Revenue Growth
- TSHA N/A
- WLKP N/A
- 52 Week Low
- TSHA $1.05
- WLKP $21.19
- 52 Week High
- TSHA $3.40
- WLKP $25.04
- Technical
- Relative Strength Index (RSI)
- TSHA 70.13
- WLKP 44.08
- Support Level
- TSHA $2.79
- WLKP $21.99
- Resistance Level
- TSHA $2.99
- WLKP $22.41
- Average True Range (ATR)
- TSHA 0.16
- WLKP 0.25
- MACD
- TSHA 0.03
- WLKP -0.02
- Stochastic Oscillator
- TSHA 93.71
- WLKP 16.85
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.